The Sixth DDI Workshop At Marbach Castle, Germany 2015 Started Yesterday With More Than 80 Experts

At the moment more than 80 drug development and interaction experts participate at the sixth International Drug-Drug Interaction Workshop and they are discussing regulatory requirements and current scientific aspects on the preclinical and clinical investigation of drug-drug interactions.

​The overall objective of the Drug-Drug Interaction Workshop series at Marbach Castle is to improve and disseminate the scientific knowledge about drug-drug interactions (incl. food-drug and herb-drug

interactions), to foster their proper preclinical and clinical investigation and communication, thereby improving the safe use of drugs in the light of ageing populations and increasing polypharmaco-therapy. The organizers of the DDI Workshop are highly pleased to see that the DDI Workshop is widely recognized and well established.

On May 03rd the sixth DDI Workshop started with a poster session and a come together dinner.

Today and tomorrow five scientific sessions are focused on drug-drug interactions involving clinical aspects, regulatory aspects, determination of intracellular drug concentrations as well as influences on drug safety. One session contains tutorials to PBPK DDI simulations and clinical trial designs. The issues will be covered by distinguished international scientists and experts from academia, pharmaceutical companies, contract research organizations, consultancies as well as government and regulatory agencies.

Robert Hermann, member of the organization team, states: “We are very proud to present a comprehensive scientific programme with five sessions and 16 speakers and chairpersons from 9 different countries. Our programme of the sixth Marbach Castle DDI Workshop will offer a scientific platform for plenty discussions around drug-drug interactions.”

One of the key aspects of the scientific meeting will be regulatory issues like the current FDA approaches to food-drug, drug-drug and gene-drug Interactions presented by Lawrence Lesko from the US as well as a speech from Anna Nordmark, Sweden to the European regulatory perspective on the use of PBPK in assessing DDIs. Another focus point will be set by Yuichi Sugiyama from Japan. He is one of the most famous and world-leading experts for transporter-induced  drug-drug interactions and he will talk about rate-determining steps in drug-drug interactions.

Other interesting talks will come from Avijit Ghosh, USA and Bernard Faller, Switzerland. They will present an overview and new data to the relevance of intracellular and tissue concentrations of medicines related to DDIs. Daniel J Antoine, UK will talk about DILI (Drug Induced Liver Injury) caused by DDIs, and Sebastian Polak, Poland will talk about the cardiac safety of medicines in conjunction with DDIs.

The DDI Workshop offers a unique opportunity for scientific exchange and networking across company and organizational boarders, and to learn about the current state-of-the-art in the investigation and clinical management of DDIs.

About the DDI Workshop
The DDI Workshop is an initiative of cr.appliance in cooperation with Hartmut Derendorf, Amin Rostami-Hodjegan, and Oliver von Richter. The meeting will take place at Marbach Castle Conference Centre, located at the Lake Constance, Germany.
The organizers of the DDI Workshop are:

  • Hartmut Derendorf, PhD FCP; College of Pharmacy, University of Florida, USA
  • Robert Hermann, MD FCP; cr.appliance, Germany
  • Amin Rostami-Hodjegan, PhD FCP; Faculty of Medical and Human Sciences, University of Manchester, UK
  • Oliver von Richter, PhD FCP; Dept. Exploratory Medicine, Merck Serono, Germany

About cr.appliance
cr.appliance is an independent team of experts that supports its clients in the healthcare industry with counseling, development concepts and services during the early stages of clinical drug development and throughout the licensing process. cr.appliance uses its well-documented, recognised expertise to the benefit of its clients.

The team of experts has undertaken successful project work in the pharmaceutical industry as well as work in the service sector (CROs), hospitals and academia. The team has a wealth of well-founded, up-to-date expertise.

This, combined with many years of professional experience in a number of specialist fields and areas of work, enables them to provide high-quality consultancy, create sustainable and viable development concepts and offer customer-specific services in various aspects of drug development.​

Contact & Information:
​Karen Grave-Hermann
Phone: +49(0)6051-97 166 91
Fax: +49(0)6051-97 166 93